Discovery Labs Up 33% After Surfaxin Approved by the FDA

Shares of Discovery Labs DSCO are up 33% after the company had its drug Surfaxin approved by the FDA. The company announced that the United States Food and Drug Administration has approved SURFAXIN for the prevention of Respiratory Distress Syndrome in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine. Discovery Labs anticipates that SURFAXIN will be commercially available in the United States in late 2012. "The approval of SURFAXIN is an important medical advancement for the neonatology community and parents of preterm infants who will soon have an effective alternative to animal-derived surfactants to prevent the development of RDS," said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs. "This is a significant milestone in our continuing efforts to develop a pipeline of products to further advance the standard of respiratory critical care."
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDAIntraday UpdateMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!